Purchase this article with an account.
Nathalie Massamba, Juliette Knoeri, Maud Elluard, Bernard Pasquier; Assessment of pain after IVT of Ranibizumab in patients undergoing AMD or CME post to diabetic retinopathy or vein occlusion.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4163.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the degree of pain of patients undergoing antiangiogenic (ranibuzumab) treatment for exudative age-related macular degeneration, CME for diabetic retinopathy, vein occlusion
Prospective, interventional, consecutive case series. We evaluate the degree of pain after ranibizumab intravitreal injection in patients undergoing exudative age-related macular degeneration (AMD), CME for diabetic retinopathy, vein occlusion during five months between May and September 2013 at Cergy hospital. The degree of pain has been evaluated only once by Visual Analog Scale Score(VAS).
80 eyes of 80 patients were analyzed between the may and july 2013 at department of ophthalmology of Cergy Hospital. The mean age of patients was 73.5, for 45 (56 %)men and 35(44%) women, with an average follow-up of 45 days. 34 eyes had AMD and 37 suffering from diabetic retinopathy and seven eyes followed for CRVO. Of the 80 eyes examined, 42 left eyes (52%) and 38 right eyes (48%). The average injection was 4.17 with an average pain rating of 1.831. 43 (54%) eyes had chirurgical history of phaco emulsification of the eye under study. Three group were identified according to arrival time, 22 (28%)eyes were injected 30 minutes after arrival (group 1) vs 29 (36%) in group 2 and 29 (36%) for group 3. The greater part of the factors analyzed were not only correlated to pain including Age, gender, site of injection, the waiting time for the injection, pathologies and the history of cataract surgery and p = were respectively (0.7;0.2;0.8;0.8;0.6;0.7). Nonetheless the number of injection was correlated to pain. p (0.07). The pain was also correlated to the injected eye, patients injected in the LE have experienced more pain than those injected in RE (0.02).
Pain is a complex phenomenon that poses a problem of definition. The I A.S.P (International Associationfor Study of Pain (pain)) proposes to define the pain as a subjective sensory experience and unpleasant emotional harm associated tissue present or potential, such damage. This definition is also used by O. m.s (World Health Organization). Many patients experience pain after intravitreal injection of ranibizumab, therefore the interest of this study was to improve our understanding of the concept of pain due to the intravitreal injection of ranibizumab in the treatment management of our patients.
This PDF is available to Subscribers Only